An analysis of the pharmacokinetics of high dose intravenous Melphalan in multiple myeloma.

被引：0
|
作者：
Kalakonda, N [1 ]
Welby-Everard, P [1 ]
Dougal, M [1 ]
Ranson, M [1 ]
Scarffe, JH [1 ]
Chopra, R [1 ]
机构：
[1] Christie Hosp, Dept Haematol & Oncol, Manchester, Lancs, England
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4661
引用
收藏
页码：321B / 321B
页数：1
相关论文
共 50 条
  • [1] MULTIPLE-MYELOMA TREATED WITH HIGH-DOSE INTRAVENOUS MELPHALAN
    SELBY, PJ
    MCELWAIN, TJ
    NANDI, AC
    PERREN, TJ
    POWLES, RL
    TILLYER, CR
    OSBORNE, RJ
    SLEVIN, ML
    MALPAS, JS
    BRITISH JOURNAL OF HAEMATOLOGY, 1987, 66 (01) : 55 - 62
  • [2] Dose dense Dreifach*Melphalan100 for multiple myeloma.
    Berz, David
    McCormack, Elise M.
    Winer, Eric S.
    Karwan, Patricia
    Colvin, Gerald
    Rathore, Ritesh
    Lum, Larry
    Abedi, Mehrdad
    Elfenbein, Gerald
    Quesenberry, Peter J.
    BLOOD, 2006, 108 (11) : 462B - 462B
  • [3] Blood stem cell mobilization with intravenous melphalan in patients with multiple myeloma.
    Osman, K
    Drake, L
    Costello, S
    Reich, L
    Wuest, D
    Klimek, V
    Kewalramani, T
    Gucciardo, A
    Fleisher, M
    Martinez, C
    Zhang, Y
    Dhodapkar, M
    Nimer, SD
    Comenzo, RL
    BLOOD, 2001, 98 (11) : 180A - 180A
  • [4] Effect of Obesity and Renal Insufficiency On Toxicity of High-Dose Melphalan for Multiple Myeloma.
    Vogl, Dan T.
    Paul, Thomas M.
    Stoopler, Eric
    Salazar, Gentian
    Davis, Lisa
    Kapoor, Shiv
    Zemel, Babette
    Yudkoff, Mark
    Jackson, Gail
    Basel-Brown, Lisa
    Rockwell, Kenneth
    Daikhin, Evgueni
    Swider, Cezary R.
    Washington, John
    Raguza-Lopez, Maria
    Tenhave, Thomas
    Stadtmauer, Edward A.
    BLOOD, 2009, 114 (22) : 483 - 484
  • [5] A phase I/II study of bortezomib and low dose intravenous melphalan (BM) for relapsed multiple myeloma.
    Popat, R
    Oakervee, HE
    Foot, N
    Agrawal, S
    Smith, P
    Craddock, C
    Williams, C
    Basu, S
    Cavenagh, JD
    BLOOD, 2005, 106 (11) : 718A - 718A
  • [6] Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy
    Nath, Christa E.
    Shaw, Peter J.
    Trotman, Judith
    Zeng, Lihua
    Duffull, Stephen B.
    Hegarty, Gareth
    McLachlan, Andrew J.
    Gurney, Howard
    Kerridge, Ian
    Kwan, Yiu Lam
    Presgrave, Peter
    Tiley, Campbell
    Joshua, Douglas
    Earl, John
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (05) : 484 - 497
  • [7] Comparison of high dose melphalan and a more intensive regimen of thiotepa, busulfan and cyclophosphamide in multiple myeloma.
    Anagnostopoulos, A
    Aleman, A
    Ayers, D
    Williams, P
    Xin, L
    Donato, M
    Alexanian, R
    Champlin, R
    Giralt, S
    BLOOD, 2002, 100 (11) : 436A - 436A
  • [8] High dose melphalan followed by busulphan-cyclofosfamide and stem cell rescue in multiple myeloma.
    Huijgens, PC
    Ossenkoppele, GJ
    Jonkhoff, AR
    Legdeur, MCJC
    Zweegman, S
    Gloudemans, IJM
    BLOOD, 1996, 88 (10) : 3860 - 3860
  • [9] A phase I/II trial of bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma.
    Popat, Rakesh
    Williams, Catherine
    Cook, Mark
    Craddock, Charles
    Basu, Supratik
    Singer, Charles
    Odeh, Liz
    Foot, Nicola
    Oakervee, Heather
    Cavenagh, James D.
    BLOOD, 2006, 108 (11) : 1011A - 1011A
  • [10] High-dose chemotherapy with sequential double cycles of cyclophosphamide and melphalan in patients with multiple myeloma.
    Nowrousian, MR
    Wrzeciono, T
    Tewes, M
    Fossa, A
    Welt, A
    Schuett, P
    Brandhorst, D
    Kloke, O
    Schuette, J
    Seeber, S
    BLOOD, 2000, 96 (11) : 421A - 421A
12345